Literature DB >> 21691888

Unblinding plan of PROWESS-SHOCK trial.

V Marco Ranieri, B Taylor Thompson, Simon Finfer, Philip S Barie, Jean-François Dhainaut, Ivor S Douglas, Bengt Gårdlund, John C Marshall, Andrew Rhodes.   

Abstract

Mesh：

Year:  2011        PMID： 21691888     DOI： 10.1007/s00134-011-2272-7

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  2 in total

1.  Statistical analysis plan of PROWESS SHOCK study.

Authors:  B Taylor Thompson; V Marco Ranieri; Simon Finfer; Philip S Barie; Jean-Francois Dhainaut; Ivor S Douglas; Bengt Gårdlund; John C Marshall; Andrew Rhodes
Journal:  Intensive Care Med       Date:  2010-08-06       Impact factor: 17.440

2.  Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

Authors:  Simon Finfer; V Marco Ranieri; B Taylor Thompson; Philip S Barie; Jean-François Dhainaut; Ivor S Douglas; Bengt Gårdlund; John C Marshall; Andrew Rhodes
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440
  2 in total
  3 in total

Review 1.  The intensive care medicine research agenda on septic shock.

Authors:  Anders Perner; Anthony C Gordon; Derek C Angus; Francois Lamontagne; Flavia Machado; James A Russell; Jean-Francois Timsit; John C Marshall; John Myburgh; Manu Shankar-Hari; Mervyn Singer
Journal:  Intensive Care Med       Date:  2017-05-12       Impact factor: 17.440

Review 2.  Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.

Authors:  Arturo J Martí-Carvajal; Ivan Solà; Christian Gluud; Dimitrios Lathyris; Andrés Felipe Cardona
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 3.  Recombinant human activated protein C for severe sepsis in neonates.

Authors:  Ranjit I Kylat; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.